On 10 November 2026 the Federal Trade Commission filed an amended complaint in its suit against telehealth company Hims & Hers Health, Inc. It adds Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs alongside Utah and California. The FTC's announcement says the Commission voted 2-0 to authorize the filing in the Northern District of California. The allegations are unproven, and the company says it will defend itself.
What is alleged
The complaint has two halves. The privacy half alleges that Hims shared consumers' sensitive health information with advertising platforms, including Meta and Snap, despite telling consumers their privacy would be protected. The billing half alleges that consumers were charged for prescriptions almost immediately after an intake form, and that cancelling was made difficult.
Trade coverage of the amended filing supplies the scale. According to PPC Land's account of the complaint, Hims uploaded roughly 14 million consumer email addresses to Meta between September 2020 and June 2023, and Meta matched about 10 million of them to user IDs. The complaint also alleges that conversion events such as "Complete Registration" and "Purchase" went to Meta through tracking tools about 8 million times. PYMNTS reports that the information concerned treatments such as erectile dysfunction and mental health care. Meta and Snap are named as recipients, but the only defendant is Hims.
The legal theories are the FTC Act, the Restore Online Shoppers' Confidence Act (ROSCA), and each state's consumer protection law. The FTC's release does not mention the Health Breach Notification Rule.
The strongest case for the enforcers
The argument for aggressive enforcement is strong. The US has no comprehensive federal privacy statute. HIPAA covers providers and insurers, not the advertising pipes a consumer's browsing data flows through. A person who fills in a questionnaire about a sensitive condition reasonably expects it to stay between them and a clinician. If a company promises privacy and then feeds the same information to ad platforms, that is a straightforward deception, and the usual consumer-protection remedies should apply. Seven state plaintiffs also show that the concern is not confined to one capital.
Why the approach deserves cautious support
This case is more defensible than much recent privacy policymaking because of what it does not do. It does not ask a court to invent a new category of forbidden data flow. It asks whether a company's statements matched its conduct, which is a familiar and evidence-based test. The FTC took the same route in its 2023 action against GoodRx, where the Commission announced its first enforcement under the Health Breach Notification Rule and a $1.5 million civil penalty for unreported disclosures of health data to Facebook, Google and others.
That approach protects innovation in two ways. First, it leaves companies free to choose their business models, including advertising-supported ones, provided they tell the truth about them. A rule-first regime that classifies every health-adjacent signal as untouchable would cut off legitimate uses such as security analytics and measurement, and it would entrench large incumbents that can afford compliance teams. Second, enforcement tied to specific promises gives startups a clear lesson: the risk lies in the gap between marketing copy and data practice, not in using modern tools.
Where the weaknesses lie
There are still reasons for caution. A deception theory is only as strong as the promise it rests on. If privacy language is vague, or a company drafts a policy that discloses broad sharing, the deception case is weaker even when the practice is more invasive. That produces a perverse incentive to write longer, more hedged policies that nobody reads, which does not help consumers.
The patchwork is another concern. Seven state plaintiffs plus a federal agency, each with different statutes, means a company can face overlapping remedies and inconsistent standards from one case. That is manageable for a large firm and punishing for a small one. A sensible federal baseline would reduce that burden, though the debate over preemption keeps stalling it.
The billing allegations also differ in kind from the privacy ones. Clear disclosure of charges and simple online cancellation are well-established norms, and ROSCA is a mature statute. Mixing the two halves in one complaint is efficient for plaintiffs, but readers should not assume that the privacy claims are as settled as the subscription claims.
What to watch
Three things will show whether this becomes a durable model.
- Which statements the court treats as promises. The ruling on the privacy claims will turn on the exact language Hims used, and that will define the safe harbour for others.
- Remedies. The amended complaint seeks a permanent injunction, a monetary judgment and civil penalties. Conduct remedies such as deleting shared data and limiting future sharing matter more for consumers than the headline sum.
- Whether ad platforms face scrutiny. Meta and Snap are named only as recipients. The question of what recipients do with uploaded customer lists is untested here.
The pro-innovation reading is that this suit works within existing law: honest marketing, honest data practices, proportionate penalties. If the court agrees, regulators will not need sweeping new health-data statutes to deal with the worst conduct. Companies that follow their own privacy promises have little to fear, and those that do not should expect states and the FTC to act together.